HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Etiracetam, (R)-
Levetiracetam EP Impurity D · LevetiracetaM IMpurity D · UCB-L 060 · Levetiracetam-4 · R-(+)-ETIRACETAM · R-(+)-LevetiracetaM · LEVETIRACETAM EP IMP D · levetiraccetam R-isomer
Identifikatoren & physikalische Daten
| CAS No. | 102767-28-2 |
|---|---|
| Summenformel | C8H14N2O2 |
| Durchschnittliche Molmasse | 170,21 g/mol |
| Monoisotopische Masse | 170,10552769 g/mol |
| SMILES | CC[C@H](C(N)=O)N1CCCC1=O |
| InChIKey | HPHUVLMMVZITSG-ZCFIWIBFSA-N |
| PubChem CID | 441341 |
| ChEMBL | CHEMBL150361 |
| EC No. | 642-991-8 |
| DTXSID | DTXSID10146044 |
Chemische & physikalische Eigenschaften
| XLogP | -0,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 63,4 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 12 |
| Formalladung | 0 |
| Komplexität | 203 |
| LogP (Verteilungskoeffizient) | -0.6 |
| Löslichkeit | 2.98e+02 g/LAcetone (Sparingly, Sonicated), Chloroform (Slightly), Methanol (Slightly) |
| Physical Description | Solid |
| Schmelzpunkt | 114-116 °C(Solv: acetone (67-64-1)) |
| Siedepunkt | 395.9±25.0 °C(Predicted) |
| Dichte | 1.168±0.06 g/cm3(Predicted) |
| Lagerbedingungen | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| pKa (Säurekonstante) | 15.74±0.50(Predicted) |
| Farbe | White to Off-White |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | 1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1 |
| InChIKey | HPHUVLMMVZITSG-ZCFIWIBFSA-N |
| SMILES | N1(CCCC1=O)[C@H](CC)C(=O)N |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 25% (1 of 4) of reports.WarningH302 (25%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (25%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (75%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (25%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]H411 (25%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 4 reports by companies.There are 3 notifications provided by 3 of 4 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (25%)Skin Irrit. 2 (25%)Eye Irrit. 2 (75%)STOT SE 3 (25%)Aquatic Chronic 2 (25%) |
| Treatment | There is no specific antidote for overdose with Levetiracetam. If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavageusual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's clinical status. |
| Gesundheitliche Auswirkungen | May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. |
Anwendungen & Verwendung
Verwenden
(R)-Levetiracetam [REV] (Levetiracetam EP Impurity D), is the enantiomer to Levetiracetam [LEV] (L331500), the antiepileptic drug that is highly enantioselective. It is apparent that [LEV] is more potent than [REV] in terms of antiepileptic potency.